Predictive value of <i>DOT1L</i> mutations for clinical outcomes in non‐small‐cell lung cancer patients receiving immune checkpoint inhibitor therapy-Reference-Cited by-同舟云学术

Predictive value of DOT1L mutations for clinical outcomes in non‐small‐cell lung cancer patients receiving immune checkpoint inhibitor therapy

Author:

Guo Tianxing¹,Wang Zhaofeng²,Wang Song³,Zhang Yaru³,Pang Jiaohui³,Ying Yajun⁴,Ou Qiuxiang³,Shen Dong⁵,Li Gang⁶⁷^ORCID

Affiliation:

1. Department of Thoracic Surgery Shengli Clinical Medical College of Fujian Medical University Fujian Provincial Hospital Fuzhou China

2. Department of Respiratory Medicine Affiliated Jinling Hospital, Medical School of Nanjing University Nanjing China

3. Geneseeq Research Institute Nanjing Geneseeq Technology Inc. Nanjing China

4. Department of Pathology Taizhou Cancer Hospital, Taizhou Zhejiang China

5. Department of Oncology The Affiliated Jiangyin Hospital of Nantong University, Jiangyin Jiangsu China

6. Department of Thoracic Surgery Sichuan Provincial People's Hospital, University of Electronic Science and Technology of China Chengdu China

7. Department of Thoracic Surgery Sichuan Translational Medicine Research Hospital, Chinese Academy of Sciences Chengdu China

Funder

Natural Science Foundation of Fujian Province

Publisher

Wiley

Subject

Molecular Medicine,Medicine (miscellaneous)

Link

Reference10 articles.